Research Article

The Effect of Apigenin on Pharmacokinetics of Imatinib and Its Metabolite N-Desmethyl Imatinib in Rats

Xian-yun Liu,¹ Tao Xu,² Wan-shu Li,³ Jun Luo,² Pei-wu Geng,² Li Wang,²
Meng-ming Xia,² Meng-chun Chen,² Lei Yu,² and Guo-xin Hu²

¹ The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China

² School of Pharmacy, Wenzhou Medical University, Wenzhou 325035, China

³ Ningbo Municipal Hospital of Traditional Chinese Medicine, Ningbo 315010, China

Correspondence should be addressed to Guo-xin Hu; hgx@wzmc.edu.cn

Received 26 June 2013; Accepted 30 October 2013

Academic Editor: Graziano Onder

Copyright © 2013 Xian-yun Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The purpose of this study was to determine the effect of apigenin on the pharmacokinetics of imatinib and N-desmethyl imatinib in rats. Healthy male SD rats were randomly divided into four groups: A group (the control group), B group (the long-term administration of 165 mg/kg apigenin for 15 days), C group (a single dose of 165 mg/kg apigenin), and D group (a single dose of 252 mg/kg apigenin). The serum concentrations of imatinib and N-desmethyl imatinib were measured by HPLC, and pharmacokinetic parameters were calculated using DAS 3.0 software. The parameters of $AUC_{(0-t)}$, $AUC_{(0-\infty)}$, T_{max} , V_z/F , and CL_z/F for imatinib in group B were different from those in group A ($P < 0.05$). Besides, $MRT_{(0-t)}$ and $MRT_{(0-\infty)}$ in groups C and D differed distinctly from those in group A as well. The parameters of $AUC_{(0-t)}$ and C_{max} for N-desmethyl imatinib in group C were significantly lower than those in group A ($P < 0.05$); however, compared with groups B and D, the magnitude of effect was modest. Those results indicated that apigenin in the short-term study inhibited the metabolism of imatinib and its metabolite N-desmethyl imatinib, while in the long-term study the metabolism could be accelerated.

1. Introduction

Imatinib (Figure 1(a)), as we know, is a phenylamino pyrimidine derivative and a member of a new class of drugs collectively known as signal transduction inhibitors which interferes with cellular proliferation and induces apoptosis of BCR-ABL cells [1]; also imatinib interferes with the receptor tyrosine kinases for platelet-derived growth factor (PDGF), stem cell factor (SCF), and c-Kit and inhibits PDGF and SCF-mediated cellular activity in vitro [2, 3].

Imatinib mesylate is approved for the treatment of chronic myeloid leukemia (CML) in blast crisis [4], the accelerated phase of disease, or in the chronic phase of disease after not responding to interferon- α therapy. Studies are also being conducted to evaluate the drug in treating gastrointestinal (GI) stromal tumors (GIST, a form of sarcoma) [5], small-cell lung cancer, prostate cancer, and glioblastoma.

The major enzyme responsible for the metabolism of imatinib is CYP3A4. Other cytochrome P450 enzymes, such

as CYP1A2, CYP2D6, CYP2C9, and CYP2C19, play a minor role in its metabolism. N-Desmethylated piperazine derivative, which is the major circulating metabolite of imatinib, possesses in vitro activity comparable to that of imatinib [6].

Apigenin is a common flavonoid presented in a variety of plants, vegetables, fruits, and herbs, some of which are widely marketed as dietary and herbal supplements [7–11]. As an antiaggregatory, antioxidant, antibacterial, and hypertension prevention substance [12–14], the chemical structure of apigenin is showed in Figure 1(b). In addition, apigenin, to some extent, is a potent inhibitor of the cytochrome P450 (CYP) enzyme system [15–17] which is responsible for the metabolism of considerable pharmaceutical drugs.

Several important and clinically relevant interactions between flavonoids and conventional drugs have been reported over the last few years. Although various biological functions of apigenin have been demonstrated in many studies, its role in health promotion mainly depends on the intake amount and bioavailability [9]. Given the widespread

Concurrent administration of other drugs or herbal products that modulate cytochrome P450 enzymes activity may alter imatinib exposure. Therefore, a combination of flavonoids and imatinib is expected. In this study, we developed a high performance liquid chromatography method for the simultaneous determination of imatinib and N-desmethyl imatinib in rat serum. The pharmacokinetics of imatinib and N-desmethyl imatinib in rats was detected after administration of apigenin.

2.6. Sample Preparation. The serum samples were prepared using liquid-liquid extraction technique. A 300 μL aliquot of the serum sample was taken in a 10 mL glass test tube, and on that 20 μL of IS (100 $\mu\text{g}/\text{mL}$) was spiked and 150 μL of sodium hydroxide solution (0.01 mol/L) was added. After vortex mixing for 30 s, 3 mL of ethyl acetate was added, and the mixture was vortexed for 1 min and then centrifuged at 3000 $\times g$ for 5 min. The organic layer was transferred into another 5 mL tube and evaporated to dryness under a stream of nitrogen gas at 40°C. The residue was reconstituted in

FIGURE 2: HPLC chromatograms of imatinib and N-desmethyl imatinib. (a) Representative chromatograms of blank serum. (b) Representative chromatograms of imatinib (5 $\mu\text{g/mL}$) and N-desmethyl imatinib (0.5 $\mu\text{g/mL}$). (c) Representative chromatograms of the serum spiked with imatinib (2.5 $\mu\text{g/mL}$) and N-desmethyl imatinib (0.25 $\mu\text{g/mL}$). (d) Representative chromatograms of the serum obtained at 3 h after a single oral dose of 30 mg/kg imatinib. A: N-desmethyl imatinib, B: imatinib, and C: phenacetin.

100 μL of mobile phase and vortex-mixed for 1 min, and 20 μL of aliquot was injected into the HPLC system for analysis.

2.7. Statistical Analysis. Experimental values were expressed as $\bar{x} \pm s$. Statistical analyses of main pharmacokinetic parameters were performed by Student's unpaired test using SPSS 16.0 software. A value of $P < 0.05$ was considered to be significant between two groups.

3. Results

3.1. Method Validation. In our study, the resolution of N-desmethyl imatinib, imatinib, and internal standard was satisfactory. No interference can be observed in the HPLC chromatograms. The retention times of N-desmethyl imatinib, imatinib, and internal standard were 4.7 min, 6.2 min, and 11.4 min, respectively. The HPLC chromatograms were shown in Figure 2.

The regression equation of imatinib was $Y_1 = 0.1905X_1 - 0.0298$ ($r = 0.9999$) and its lower limit of quantitation (LLOQ) was 0.10 $\mu\text{g/mL}$; the regression equation of N-desmethyl imatinib was $Y_2 = 0.4757X_2 - 0.0088$ ($r = 0.9997$) and its LLOQ was 0.01 $\mu\text{g/mL}$. Both intraday and interday precisions were all less than 4.90% for imatinib and 6.26% for N-desmethyl imatinib. The method showed that the relative recoveries of imatinib and N-desmethyl imatinib

were all more than 94%, whilst the absolute recoveries were all more than 76%. Blood samples at room temperature and in frozen condition showed good stability. So the method could be well applied for determinations of imatinib and N-desmethyl imatinib in rat plasma.

3.2. Effects of Long-Term 165 mg/kg Apigenin on Imatinib and N-Desmethyl Imatinib. The experiment results of pharmacokinetic parameters revealed that the data of $AUC_{(0-t)}$, $AUC_{(0-\infty)}$, $T_{\max}$, V_z/F , and CL_z/F had a significant difference between group A and group B ($P < 0.05$) (Figure 3, Table 1). To be specific, the figures of $AUC_{(0-t)}$ and $AUC_{(0-\infty)}$ in group B were 24.8% and 24.4% lower than those in group A, respectively, while the values of V_z/F and CL_z/F in group B increased by 100.1% and 31.3%. On the contrary, the main pharmacokinetic parameters of N-desmethyl imatinib had no great differences between the two groups.

3.3. Effects of Short-Term 165 mg/kg Apigenin on Imatinib and N-Desmethyl Imatinib. The main pharmacokinetic parameters of imatinib such as $AUC_{(0-t)}$, $AUC_{(0-\infty)}$, CL_z/F , and $C_{\max}$ were significantly distinct between group C and group A ($P < 0.05$) (Figure 3, Table 1). Specifically, the values of $AUC_{(0-t)}$ and $AUC_{(0-\infty)}$ in group C were 39.8% and 40.1% higher than those of group A, respectively. Concerned with V_z/F , CL_z/F , and $C_{\max}$, pharmacokinetic parameters diminished by 10.2%,

TABLE 1: The main pharmacokinetic parameters of imatinib in four groups ($n = 5$).

Parameters	A	B	C	D
$AUC_{(0-t)}$ (mg·h·L ⁻¹)	90.618 ± 11.34	68.158 ± 7.279*	126.678 ± 12.499*,**	113.095 ± 8.918*,**
$AUC_{(0-\infty)}$ (mg·h·L ⁻¹)	90.988 ± 11.585	68.805 ± 7.432*	127.514 ± 12.332*,**	114.502 ± 8.634*,**
$MRT_{(0-t)}$ (h)	5.718 ± 0.274	5.479 ± 0.512	6.121 ± 0.33**	6.049 ± 0.351**
$MRT_{(0-\infty)}$ (h)	5.804 ± 0.376	5.707 ± 0.579	6.274 ± 0.337**	6.337 ± 0.532**
$t_{(1/2)z}$ (h)	2.304 ± 0.954	3.423 ± 1.361	2.82 ± 1.069	3.456 ± 0.418
T_{max} (h)	3.0 ± 1.003	2.0 ± 0.004*	3.8 ± 0.447**	3.6 ± 0.548**
V_z/F (kg·L ⁻¹)	1.081 ± 0.372	2.163 ± 0.875*	0.971 ± 0.396**	1.315 ± 0.209**
CL_z/F (L·min ⁻¹ ·kg ⁻¹)	0.335 ± 0.051	0.44 ± 0.05*	0.237 ± 0.023*,**	0.263 ± 0.019*,**
C_{max} (mg·L ⁻¹)	12.074 ± 2.023	10.544 ± 0.931	15.583 ± 0.86*,**	14.388 ± 1.753*,**

* $P < 0.05$ in comparison to group A; ** $P < 0.05$ in comparison to group B.

TABLE 2: The main pharmacokinetic parameters of N-desmethyl imatinib in four groups ($n = 5$).

Parameters	A	B	C	D
$AUC_{(0-t)}$ (mg·h·L ⁻¹)	5.977 ± 1.626	6.335 ± 1.105	4.797 ± 0.602**	5.262 ± 0.89
$AUC_{(0-\infty)}$ (mg·h·L ⁻¹)	6.827 ± 2.595	6.672 ± 0.797	5.05 ± 0.797	5.545 ± 0.814
$MRT_{(0-t)}$ (h)	7.085 ± 1.135	6.573 ± 0.544	7.227 ± 0.525	7.326 ± 0.53
$MRT_{(0-\infty)}$ (h)	9.718 ± 4.636	7.504 ± 0.189	8.397 ± 1.545	8.679 ± 1.301
$t_{(1/2)z}$ (h)	5.495 ± 3.92	4.083 ± 0.436	4.906 ± 2.093	5.376 ± 1.495
T_{max} (h)	3.6 ± 0.894	4.0 ± 0.003	4.0 ± 0.005	3.8 ± 0.447
V_z/F (kg·L ⁻¹)	32.802 ± 10.255	26.843 ± 4.486	40.738 ± 12.777	43.512 ± 16.116**
CL_z/F (L·min ⁻¹ ·kg ⁻¹)	4.913 ± 1.782	4.552 ± 0.592	6.066 ± 0.992	5.507 ± 0.834
C_{max} (mg·L ⁻¹)	0.678 ± 0.147	0.797 ± 0.073	0.547 ± 0.091**	0.639 ± 0.13**

* $P < 0.05$ in comparison to group A; ** $P < 0.05$ in comparison to group B.

FIGURE 3: Mean concentration-time curve of imatinib in four groups ($n = 5$).

29.3%, and 29.1%, respectively; as to $t_{(1/2)z}$, the magnitude of effect was modest in group C.

Referred to the main pharmacokinetic parameters of imatinib, such as $AUC_{(0-t)}$, $AUC_{(0-\infty)}$, $MRT_{(0-t)}$, $MRT_{(0-\infty)}$, T_{max} , V_z/F , CL_z/F , and C_{max} , the results vary a lot between

group B and group C ($P < 0.05$) (Figure 3, Table 1). To be specific, the figures of $AUC_{(0-t)}$ and $AUC_{(0-\infty)}$ in group C were approximately 85% higher than the two indexes in group B. While the values of V_z/F and CL_z/F in group B both dropped a bit more decreased by 55.1% and 46.1%, respectively.

In comparison with group B, the $AUC_{(0-t)}$ and C_{max} of N-desmethyl imatinib increased by 19.7% and 19.3%, respectively (Figure 4, Table 2).

3.4. Effects of Short-Term 252 mg/kg Apigenin on Imatinib and N-Desmethyl Imatinib. Similar to group C, the parameters of imatinib in group D revealed an enormous difference from group A and group B as well, but not to the extent of that in group C. The details were displayed in Figure 3 and Table 1.

Compared with group B, the V_z/F of N-desmethyl imatinib demonstrated a decrease by 62.10%, and C_{max} which reduced by 19.82% had a similar downward trend with V_z/F (Figure 4 and Table 2).

4. Discussion

The studies mainly focused on the pharmacokinetic characteristics of imatinib and its metabolite N-desmethyl imatinib, then fitting their pharmacokinetic parameters. Two-compartment model was found to meet the concentration-time curves of imatinib and N-desmethyl imatinib in four groups.

FIGURE 4: Mean concentration-time curve of N-desmethyl imatinib in four groups ($n = 5$).

The influence of 252 mg/kg short-time apigenin group in imatinib was less than that of 165 mg/kg apigenin group, which indicated that the effect was not dose dependent. This was in good agreement with the findings of the previously published studies [18]. The authors suggested that the main part of the ingested apigenin was either excreted unabsorbed or was rapidly metabolized after absorption. Besides, the imatinib in the long-term group and short-term groups had significant differences related to $AUC_{(0-t)}$, $AUC_{(0-\infty)}$, $MRT_{(0-t)}$, $MRT_{(0-\infty)}$, V_z/F , CL_z/F , and C_{max} ($P < 0.05$). As a result, the metabolism of imatinib was inhibited by a single dose of application in vivo, while it was accelerated by a long-term oral administration of apigenin.

Natural flavonoids, such as flavone, tangeretin, and nobiletin, could affect the human CYP activities when administered orally [19]. CYP3A exhibited large interindividual variation [20] and represented the largest piece of CYP enzymes expressed in the human liver [21]. Many drug-interaction between herbal medicines and anticarcinogen may contribute to the inhibitory effect on CYP3A4 [22, 23].

Imatinib has very good oral absorption, whose oral bioavailability is close to 97% [24]. It had wide tissue distribution as well, which meant that a small change in the binding protein proportion would cause large variances in pharmacology. Imatinib is not only the substrate of CYP3A4, but also the inhibitor of CYP3A4. The plasma concentrations of CYP3A4 substrate, such as simvastatin and pimozide, may be elevated by imatinib [17]. Imatinib could not only affect CYP3A4 but also influence CYP2D6, CYP2C9, and CYP2C19 in various degrees [25–27]. The results got from the research supported that imatinib exposure was related to hematologic response; thus an increase in imatinib exposure produced by apigenin is likely to be clinically relevant and may lead to adverse drug reaction.

From the analysis, the results also indicated that a single dose administration could reduce the metabolism rate of imatinib, increase bioavailability, and extend the resistance time of prototype drug in vivo. Those changes might be related to a potential interaction between apigenin and CYP enzymes.

Given the widespread availability of apigenin, it was important to understand what effects its concomitant use might have on the disposition of imatinib; therefore, the research was carried out as expected.

5. Conclusion

In summary, patients taking imatinib should pay attention to the intake of the food with apigenin. The inhibitory effects of single-dose apigenin would result in higher concentrations of imatinib in the short term but lower in the long term exposure. Attention has to be paid on the dose adjustments in order to reduce the adverse reaction of drug interactions when apigenin and imatinib are administrated concurrently. Up to now, there are few reports about the effects of traditional Chinese medicine and food composition on imatinib metabolism. All above results showed preponderance of the evidence for clinical rational use of imatinib, and provided a new perspective for the understanding of apigenin.

Conflict of Interests

None of the authors has any conflict of interests related to this paper.

Authors' Contribution

Xian-yun Liu and Tao Xu contributed equally to this work.

Acknowledgment

This research was partially supported by the one Grant funded by the Ministry of Health of China (201302008).

References

- [1] J. Wu, F. Meng, H. Lu et al., "Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells," *Blood*, vol. 111, no. 7, pp. 3821–3829, 2008.
- [2] M. G. Kris, R. B. Natale, R. S. Herbst et al., "Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial," *The Journal of the American Medical Association*, vol. 290, no. 16, pp. 2149–2158, 2003.
- [3] J. Litz and G. W. Krystal, "Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1 α activity and vascular endothelial growth factor expression in small cell lung cancer cells," *Molecular Cancer Therapeutics*, vol. 5, no. 6, pp. 1415–1422, 2006.
- [4] M. Talpaz, N. P. Shah, H. Kantarjian et al., "Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias," *The New England Journal of Medicine*, vol. 354, no. 24, pp. 2531–2541, 2006.

- [5] G. D. Demetri, M. von Mehren, C. D. Blanke et al., "Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors," *The New England Journal of Medicine*, vol. 347, no. 7, pp. 472–480, 2002.
- [6] H. Burger and K. Nooter, "Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib," *Cell Cycle*, vol. 3, no. 12, pp. 1502–1505, 2004.
- [7] I. N. Beara, M. M. Lesjak, E. D. Jovin et al., "Plantain (*Plantago L.*) species as novel sources of flavonoid antioxidants," *Journal of Agricultural and Food Chemistry*, vol. 57, no. 19, pp. 9268–9273, 2009.
- [8] C. Li, H. Du, L. Wang et al., "Flavonoid composition and antioxidant activity of tree peony (*Paeonia* section *Moutan*) yellow flowers," *Journal of Agricultural and Food Chemistry*, vol. 57, no. 18, pp. 8496–8503, 2009.
- [9] X. Y. Lu, D. L. Sun, Z. J. Chen et al., "Relative contribution of small and large intestine to deglycosylation and absorption of flavonoids from *Chrysanthemum morifolium* extract," *Journal of Agricultural and Food Chemistry*, vol. 58, no. 19, pp. 10661–10667, 2010.
- [10] G. Panoino, F. L. Courts, S. Lombardo, G. Mauromicale, and G. Williamson, "Caffeoylquinic acids and flavonoids in the immature Inflorescence of globe artichoke, wild cardoon, and cultivated cardoon," *Journal of Agricultural and Food Chemistry*, vol. 58, no. 2, pp. 1026–1031, 2010.
- [11] Y. Qiu, Q. Liu, and T. Beta, "Antioxidant activity of commercial wild rice and identification of flavonoid compounds in active fractions," *Journal of Agricultural and Food Chemistry*, vol. 57, no. 16, pp. 7543–7551, 2009.
- [12] S. Matsumoto, S. Kimura, H. Segawa et al., "Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines," *Lung Cancer*, vol. 47, no. 1, pp. 31–39, 2005.
- [13] T. Tarumoto, T. Nagai, K. Ohmine et al., "Ascorbic acid restores sensitivity to imatinib via suppression of Nrf2-dependent gene expression in the imatinib-resistant cell line," *Experimental Hematology*, vol. 32, no. 4, pp. 375–381, 2004.
- [14] W. Du, C. Sun, Z. Liang, Y. Han, and J. Yu, "Antibacterial activity of hypocrellin A against *Staphylococcus aureus*," *World Journal of Microbiology and Biotechnology*, vol. 28, no. 11, pp. 3151–3157, 2012.
- [15] P. Lampropoulos, M. Lambropoulou, A. Papalois et al., "The role of apigenin in an experimental model of acute pancreatitis," *Journal of Surgical Research*, vol. 183, no. 1, pp. 129–137, 2013.
- [16] H. Shimada, M. Eto, M. Ohtaguro et al., "Differential mechanisms for the inhibition of human cytochrome P450 1A2 by apigenin and genistein," *Journal of Biochemical and Molecular Toxicology*, vol. 24, no. 4, pp. 230–234, 2010.
- [17] P. C. Ho, D. J. Saville, and S. Wanwimolruk, "Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds," *Journal of Pharmacy and Pharmaceutical Sciences*, vol. 4, no. 3, pp. 217–227, 2001.
- [18] M. Hellen, B. Adrian, and W. Guenther, "Bioavailability of apigenin from apiin-rich parsley in humans," *Annals of Nutrition and Metabolism*, vol. 50, no. 3, pp. 167–172, 2006.
- [19] P. Hodek, P. Trefil, and M. Stiborová, "Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450," *Chemico-Biological Interactions*, vol. 139, no. 1, pp. 1–21, 2002.
- [20] C. M. Hunt, W. R. Westerkam, and G. M. Stave, "Effect of age and gender on the activity of human hepatic CYP3A," *Biochemical Pharmacology*, vol. 44, no. 2, pp. 275–283, 1992.
- [21] J. Li, M. O. Karlsson, J. Brahmer et al., "CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors," *Journal of the National Cancer Institute*, vol. 98, no. 23, pp. 1714–1723, 2006.
- [22] C. S. Yang, J. D. Lambert, and S. Sang, "Antioxidative and anticarcinogenic activities of tea polyphenols," *Archives of Toxicology*, vol. 83, no. 1, pp. 11–21, 2009.
- [23] Y. J. Surh and L. R. Ferguson, "Dietary and medicinal antimutagens and anticarcinogens: molecular mechanisms and chemopreventive potential—highlights of a symposium," *Mutation Research*, vol. 523–524, pp. 1–8, 2003.
- [24] I. Panigrahi and R. Naithani, "Imatinib mesylate: a designer drug," *Journal of Association of Physicians of India*, vol. 54, pp. 203–206, 2006.
- [25] Y. Wang, L. Zhou, C. Dutreix et al., "Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia," *British Journal of Clinical Pharmacology*, vol. 65, no. 6, pp. 885–892, 2008.
- [26] Y. Yamakawa, A. Hamada, R. Nakashima et al., "Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia," *Therapeutic Drug Monitoring*, vol. 33, no. 2, pp. 244–250, 2011.
- [27] A. M. Filppula, M. Neuvonen, J. Laitila, P. J. Neuvonen, and J. T. Backman, "Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response," *Drug Metabolism and Disposition*, vol. 41, no. 1, pp. 50–59, 2013.